Secondary Malignancy After Urologic Reconstruction Procedures: A Multi-Institutional Case Series

2021 ◽  
Author(s):  
Chelsea Cornell ◽  
Francesca Khani ◽  
Adeboye O. Osunkoya ◽  
Andres Matoso ◽  
Hiroshi Miyamoto ◽  
...  
Keyword(s):  
Case Series ◽  
Secondary Malignancy

scholarly journals Low dose continuous lenalidomide in heavily pretreated patients with relapsed or refractory classical Hodgkin lymphoma: a retrospective case series

2020 ◽  
Vol 11 ◽  
pp. 204062072094734
Author(s):  
Helen Ma ◽  
Bin Cheng ◽  
Francesca Montanari ◽  
Jennifer K. Lue ◽  
Changchun Deng ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Patient Population ◽  
Low Dose ◽  
Case Series ◽  
Progression Free Survival ◽  
Secondary Malignancy ◽  
Cell Transplant ◽  
Toxicity Profile ◽  
Classical Hodgkin Lymphoma ◽  
Retrospective Case

Patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) following autologous stem cell transplant (ASCT) remain a management challenge with few reliably effective treatments. Lenalidomide, an immunomodulatory drug approved for patients with myelodysplastic syndrome with del(5q), multiple myeloma, and mantle cell lymphoma, has demonstrated some activity in patients with R/R cHL, though the toxicity of traditional doses and schedules has been a barrier to consistent use. Low dose continuous (LDC) schedules have emerged as promising, with a more favorable safety profile. We report herein that LDC schedules are associated with a far more tolerable toxicity profile, and exhibit at least equivalent efficacy in this patient population. We report that patients diagnosed with R/R cHL who previously underwent, or were not candidates for, ASCT and/or clinical trials, were administered daily LDC lenalidomide (20 mg orally with dose reduction for toxicity). Among the 19 patients included in this analysis, 11% of patients achieved a partial response (PR), with no documented complete responses (CR). A total of 12 (63%) patients maintained stable disease (SD), with 7 patients (37%) remaining in SD for more than 6 months. The clinical benefit rate (comprised of CR, PR, and SD for greater than 6 months) was 47% (7 out of 19 patients). The median progression-free survival and overall survival of all patients were 9.4 months (range, 4.6–14.4 months) and 90 months (range, 63.6–166.8 months), respectively. In general, the treatment was well tolerated, with grade 3 or 4 adverse events consisting of neutropenia ( n = 4), and one case each of thrombocytopenia, fatigue, rash, creatinine elevation, aspartate transaminase/alanine transaminase elevation, and treatment related secondary malignancy. In a heavily treated R/R cHL patient population, daily LDC lenalidomide was associated with a high disease control rate with a favorable toxicity profile.

scholarly journals A case series on the role of 18F-FDG PET/CT-guided biopsy of osseous metastases

2021 ◽  
Vol 5 (1) ◽  
Author(s):  
Michael Farrell ◽  
Gina Hyun ◽  
Michael P. Goold ◽  
Pavel Krapiva
Keyword(s):  
Case Series ◽  
Final Diagnosis ◽  
Secondary Malignancy ◽  
Molecular Testing ◽  
Primary Malignancy ◽  
Ct Guided ◽  
Osseous Metastases ◽  
Guided Biopsy ◽  
Pet Ct ◽  
Ct Guided Biopsy

Abstract Purpose This case series explores the utility of positron emission tomography (PET)/computed tomography (CT) guidance for biopsy of 18F-fludeoxyglucose (FDG)-avid osseous lesions that are inconspicuous on CT. Methods PET/CT-guided core biopsies were performed in four patients with suspected malignancies given 18F-FDG-avid osseous lesions that were inconspicuous on CT alone. The final diagnosis for each patient was determined by histopathological and molecular testing. Results PET/CT-guided biopsy yielded accurate sampling via core needle biopsy (CNB) with histopathological confirmation of osseous metastases of the primary malignancy as opposed to a secondary malignancy in three patients and ruled-out metastatic spread in the fourth. Conclusion PET/CT-guided biopsy of hypermetabolic osseous lesions that are inconspicuous on CT alone is an effective and safe diagnostic tool in patients with suspected malignancy.

scholarly journals PD-1 inhibition in malignant melanoma and lack of clinical response in chronic lymphocytic leukemia in the same patients: a case series

2020 ◽  
Vol 27 (3) ◽  
Author(s):  
I. Landego ◽  
D. Hewitt ◽  
I. Hibbert ◽  
D. Dhaliwal ◽  
W. Pieterse ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Chronic Lymphocytic Leukemia ◽  
Meta Analysis ◽  
Case Series ◽  
Fold Increase ◽  
Lymphocytic Leukemia ◽  
Western World ◽  
Secondary Malignancy ◽  
Increased Risk ◽  
Adult Leukemia

Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the western world. Unfortunately these patients are often immunosuppressed and at increased risk of infection and secondary malignancy. Previous meta-analysis has found that patients with CLL are at a four-fold increase of melanoma compared to the general population. Recent advancements in our understanding of the programmed death (PD) receptor pathway have led to the advent of immunotherapies to target cancer cells. The use of PD-1 inhibitors is now considered first line treatment for BRAF wild-type metastatic melanoma. Interestingly, early pre-clinical data suggest that inhibition of this pathway may also be used in the treatment of CLL, however clinical trials now published were not successful. In this case series we highlight two cases where patients with CLL and concurrent malignant melanoma undergo treatment with PD-1 inhibitors, and were found to have reductions in their WBC counts but these were not sustained. These cases further illustrate that treatment of CLL with PD-1 inhibitors are ineffective treatment alone.

scholarly journals Chronic Myeloid Leukemia as Secondary Malignancy Following the Treatment of Hodgkin Lymphoma: A Case Series

2019 ◽  
Vol 39 (8) ◽  
pp. 4333-4335 ◽  
Author(s):  
RALPH MILLETT ◽  
ANITA AGGARWAL ◽  
IMAD TABBARA ◽  
SAMAH NASSEREDDINE
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Hodgkin Lymphoma ◽  
Myeloid Leukemia ◽  
Case Series ◽  
Secondary Malignancy

Abstract #856 A Case Series Review of Clinical and Biochemical Characteristics of Pituitary Abcess in Mexican Patients

2018 ◽  
Vol 24 ◽  
pp. 202-203
Author(s):  
Mireya Perez-Guzman ◽  
Alfredo Nava de la Vega ◽  
Arturo Pena Velarde ◽  
Tania Raisha Torres Victoria ◽  
Froylan Martinez-Sanchez ◽  
...  
Keyword(s):  
Case Series ◽  
Biochemical Characteristics ◽  
Mexican Patients

Cannabis-associated arteritis

VASA ◽  
2010 ◽  
Vol 39 (1) ◽  
pp. 43-53 ◽  
Author(s):  
Grotenhermen
Keyword(s):  
Systematic Review ◽  
Case Reports ◽  
Case Series ◽  
Cardiovascular Effects ◽  
Causative Factor ◽  
Cannabis Use ◽  
Thromboangiitis Obliterans ◽  
Pathological Features ◽  
Scientific Support ◽  
Clinical And Pathological Features

Background: To investigate the hypothesis that cases of arteritis similar to thromboangiitis obliterans (TAO) and associated with the use of cannabis were caused by cannabis or THC (dronabinol), or that cannabis use is a co-factor of TAO. Patients and methods: A systematic review on case reports and the literature on so-called cannabis arteritis, TAO, and cardiovascular effects of cannabinoids was conducted. Results: Fifteen reports with 57 cases of an arteritis associated with the use of cannabis and two additional case series of TAO, in which some patients also used cannabis, were identified. Clinical and pathological features of cannabis-associated arteritis do not differ from TAO and the major risk factor of TAO, tobacco use, was present in most, if not in all of these cases. The proposed pathophysiological mechanisms for the development of an arteritis by cannabis use are not substantiated. Conclusions: The hypothesis of cannabis being a causative factor or co-factor of TAO or an arteritis similar to TAO is not supported by the available evidence. The use of the term “cannabis arteritis” should be avoided until or unless more convincing scientific support is forthcoming.

Sign in / Sign up

Export Citation Format

Share Document